ROBERT WOLLENZIEN: Open Payments
NPI 1831674092 · SALEM, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,730 in 140 payments from 22 companies in 2025. Trend: 2023 $1,803 · 2024 $2,231 · 2025 $1,730
Food & beverage: $1,730
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $354 |
| AstraZeneca Pharmaceuticals LP | 8 | $205 |
| Astellas Pharma US Inc | 9 | $180 |
| Novo Nordisk Inc | 21 | $177 |
| Lilly USA, LLC | 26 | $125 |
| Axsome Therapeutics, Inc. | 7 | $123 |
| Otsuka America Pharmaceutical, Inc. | 7 | $104 |
| GlaxoSmithKline, LLC. | 5 | $80 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $67 |
| Novartis Pharmaceuticals Corporation | 3 | $61 |
Products named: Veozah, VRAYLAR, FARXIGA, REXULTI, MOUNJARO, Sunosi, UBRELVY, QULIPTA.
Industry payments across UT — which companies pay providers there.
